title: Evaluation of renal masses with contrast-enhanced rapid acquisition spin echo MR imaging.
abstract: To assess the use of dynamic contrast-enhanced rapid acquisition spin-echo (RASE) imaging for the detection and characterization of renal masses, we evaluated 18 patients with CT evidence of 67 renal masses. The masses included 58 simple cysts, 8 solid neoplasms, and 1 pseudotumor. Patients were examined with standard spin-echo (SE) pulse sequences including pre- and postcontrast T1-weighted images and noncontrast T2-weighted images as well as pre- and postcontrast RASE images. Each pulse sequence was reviewed individually and in a group with other pulse sequences by two blinded observers. The performance of contrast-enhanced RASE imaging either alone or in combination with a T2-weighted SE sequence resulted in improved diagnostic accuracy compared with unenhanced conventional SE and RASE sequences. The contrast-enhanced RASE sequence outperformed the contrast-enhanced T1-weighted SE sequence for one observer; similar diagnostic accuracy was achieved with the two examinations by the other observer. Combining the T2-weighted sequence with contrast-enhanced RASE images did not increase lesion detection but did increase the observers' confidence in making the diagnosis. Contrast-enhanced MR imaging resulted in significant improvement in the detection and characterization of renal lesions compared to unenhanced MR imaging.
authors.affiliation: Tri City Medical Center, Oceanside, CA 92056.
authors.forename: S S
authors.initials: SS
authors.lastname: Eilenberg
authors.forename: J J
authors.initials: JJ
authors.lastname: Brown
authors.forename: J K
authors.initials: JK
authors.lastname: Lee
authors.forename: J P
authors.initials: JP
authors.lastname: Heiken
authors.forename: S A
authors.initials: SA
authors.lastname: Mirowitz
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002292:Carcinoma, Renal Cell / Q000175:diagnosis* / Q000453:epidemiology; D003287:Contrast Media; D004338:Drug Combinations; D005260:Female; D005682:Gadolinium; D019786:Gadolinium DTPA; D006222:Hamartoma / Q000175:diagnosis* / Q000453:epidemiology; D006801:Humans; D007668:Kidney / Q000000981:diagnostic imaging / Q000473:pathology; D052177:Kidney Diseases, Cystic / Q000175:diagnosis* / Q000453:epidemiology; D007680:Kidney Neoplasms / Q000175:diagnosis* / Q000453:epidemiology; D008279:Magnetic Resonance Imaging / Q000295:instrumentation / Q000379:methods* / Q000706:statistics & numerical data; D008297:Male; D008536:Meglumine; D008875:Middle Aged; D015588:Observer Variation; D009942:Organometallic Compounds; D004369:Pentetic Acid; D012372:ROC Curve; D013997:Time Factors; D014057:Tomography, X-Ray Computed / Q000295:instrumentation / Q000379:methods / Q000706:statistics & numerical data
chemical_list: D003287:Contrast Media; D004338:Drug Combinations; D009942:Organometallic Compounds; D008536:Meglumine; D004369:Pentetic Acid; D005682:Gadolinium; D019786:Gadolinium DTPA